Drugs Made In America Acquisition Ii (DMIIU) Annual Balance Sheets

Annual · GAAP · USD millions
Access DMIIU quarterly Balance Sheets →
This balance sheet overview for Drugs Made In America Acquisition Ii spans from to Dec 31 2025, showing how the company's assets, liabilities, and equity have evolved across reporting periods.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
Assets
Cash & cash equivalent0.00
Cash & Short-term Investments0.00
Prepaid Expense, Current AS0.03
Total Current Assets0.03
Other Assets, Noncurrent504.93
Total Assets504.96
Liabilities
Accounts Payable, Current AC0.10
Accrued Liabilities, Current AC0.09
Other Liabilities, Current0.00
Total Current Liabilities0.30
Total Long-term Debt0.00
Accrued Offering Costs0.11
Deferred Underwriting Fees Payable17.50
Total Liabilities17.80
Stockholders' Equity
Common Stock Value0.00
Retained Earnings / Accumulated Deficit-17.78
Other Equity-504.93
Common Stockholder's Equity-522.71
Non-controlling interests & other504.93
Total Stockholder's Equity-17.77
Liabilities & Stockholder's Equity504.96
4 historic quarters locked

Sign in to unlock the full Drugs Made In America Acquisition Ii balance sheet history.

About Drugs Made In America Acquisition Ii Corp Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001213900-26-044055

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License